Cervical cancer prevention in Saudi Arabia: It is time to call for action!

Open Women's Health Journal

Volumn 6, Issue 1, 2012, Pages 1-5

  Sait, Khalid ^a   Bentley, James ^b   Anfinan, Nisrin ^a   Power, Patti ^c  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cervical cancer; Prevention; Saudi Arabia

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL PRACTICE; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; NONHUMAN; ONSET AGE; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRENATAL CARE; PRIORITY JOURNAL; SAUDI ARABIA; SCREENING TEST; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; WOMEN'S HEALTH;

EID: 84860688256     PISSN: None     EISSN: 18742912     Source Type: Journal    
DOI: 10.2174/1874291201206010001     Document Type: Article

References (40)

1. http://www.nationmaster.com/country/sa-saudi-arabia/Age-_distribution
2. World Health Organization. Human papillomavirus infection and cervical cancer. Geneva: WHO 2003; pp. 1-74. Available from: http://www.who.int/vaccine_research/diseases/hpv/en [Accessed on January 13, 2011]
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
4. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994; 271(23): 1866-1869.
5. Cancer Incidence Report Saudi Arabia 2005. Available at www.scr.org.sa/reports/SCR2007.pdf [Accessed on June 26, 2011]
6. Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer 2001; 11(1): 24-31.
7. Sankaranarayanan R, Swaminathan R, Jayant K, Brenner H. An overview of cancer survival in Africa, Asia, the Caribbean and Central America: the case for investment in cancer health services. IARC Sci Publ 2011; 162: 257-291.
8. Al-Jaroudi D, Hussain TZ. Prevalence of abnormal cervical cytology among subfertile Saudi women. Ann Saudi Med 2010; 30(5): 397-400.
9. Jamal A, Al-Maghrabi JA. Profile of Pap smear cytology in the Western region of Saudi Arabia. Saudi Med J 2003; 24(11): 1225-1229.
10. Altaf FJ. Pattern of cervical smear cytology in the Western region of Saudi Arabia. Ann Saudi Med 2001; 21(1/2): 92-96.
11. Abdullah LS. Pattern of abnormal Pap smears in developing countries: a report from a large referral hospital in Saudi Arabia using the revised 2001 Bethesda System. Ann Saudi Med; 27(4): 268-272.
12. Altaf FJ. Cervical cancer screening with pattern of pap smear. Review of multicenter studies. Saudi Med J 2006; 27(10): 1498-1502.
13. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184(1): 9-13.
14. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. Inter-national biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87(11): 796-802.
15. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-19.
16. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-527.
17. Al-Muammar T, Al-Ahdal MN, Hassan A, Kessie G, Dela Cruz DM, Mohamed GE. Human papilloma virus-16/18 cervical infection among women attending a family medical clinic in Riyadh. Ann Saudi Med 2007; 27(1): 1-5.
18. Gazzaz FB. Molecular testing of human papillomavirus in cervical specimens. Saudi Med J 2007; 28(12): 1810-1818.
19. Alsbeih G, Ahmed R, Al-Harbi N, Venturina LA, Tulbah A, Balaraj K. Prevalence and genotypes' distribution of human papillomavirus in invasive cervical cancer in Saudi Arabia. Gynecol Oncol 2011; 121(3): 522-526. Epub 2011 Feb 24.
20. Darnel AD, Wang D, Ghabreau L, et al. Correlation between the presence of high-risk human papillomaviruses and Id gene expression in Syrian women with cervical cancer. Clin Microbiol Infect 2010; 16(3): 262-266.
21. Sait K, Gazzaz F. Molecular tests to detect human papilloma virus infection in patients with cervical dysplasia and invasive cervical cancer in Saudi Arabia. Pathol Lab Med Int 2011; 3: 25-29.
22. Raza SA, Franceschi S, Pallardy S, et al. Human papillomavirus infection in women with and without cervical cancer in Karachi, Pakistan. Br J Cancer 2010; 102(11): 1657-1660.
23. El Dosoky M, Ismail N, Dagastani M. Preinvasive cervical carcinoma in Saudi Arabia. Lancet 1995; 345(8950): 650.
24. Manji M. Cervical cancer screening program in Saudi Arabia: action is overdue. Ann Saudi Med 2000; 20(5/6): 355-357.
25. Kitchener HC, Symonds P. Detection of cervical intraepithelial neoplasia in developing countries. Lancet 1999; 353(9156): 856-857.
26. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008 May; 9(5): 425-434.
27. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109(2 Suppl): S15-S21.
28. Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010; 10(50): 7-17.
29. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009; 8(12): 1663-1679.
30. Kim JJ, Salomon JA, Weinstein MC, Goldie SJ. Packaging health services when resources are limited: the example of a cervical cancer screening visit. PLoS Med 2006; 3: 2031.
31. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001; 285(24): 3107-3015. Erratum: JAMA 2001; 286(9): 1026.
32. Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in lessdeveloped countries. J Natl Cancer Inst 2002; 94(19): 1469-1483.
33. EngenderHealth. Cervical Health Implementation Project, South Africa. Technical Report. Cape Town: University of Wiwatersrand, University of Cape Town and Enger-Health 2003.
34. Denny L, Kuhn L, Pollack A, Wright TC Jr. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer 2002; 94(6): 1699-1707.
35. Gaffikin L, Lauterbach M, Blumenthal PD. Performance of visual inspection with acetic acid for cervical cancer screening: a qualitative summary of evidence to date. Obstet Gynecol Surv 2003; 58(8): 543-550.
36. Sankaranarayanan R, Basu P, Wesley RS, et al. IARC Multicentre Study Group on Cervical Cancer Early Detection. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 2004; 110(6): 907-913.
37. Blumenthal PD, Lauterbach M, Sellors JW, Sankaranarayanan R. Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy. Int J Gynaecol Obstet 2005; 89(Suppl 2): S30-S37.
38. Sarian LO, Derchain SF, Naud P, et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study. J Med Screen 2005; 12(3):142-149.
39. Shun-Zhang Y, Miller AB, Sherman GJ. Optimising the age, number of tests, and test interval for cervical screening in Canada. J Epidemiol Community Health 1982; 36(1): 1-10.
40. Confortini M, Giorgi Rossi P, Barbarino P, Passarelli AM, Orzella L, Tufi MC. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. J Med Screen 2010; 17(2): 79-86.